GMP IPO
📋 Filings Intelligence
About Contact
LIVE - Auto-updated every 10 mins · Equity segment
Company Filings, Explained Simply

AI-powered plain-English analysis of every important corporate announcement - financial results, order wins, dividends, mergers and more. Updated live.

-
Filed today
-
Companies tracked
NSE & BSE
Listed on
Sign in free to search by company
Filing Type
Market Cap
Sector
All Sectors

Latest Filings -

📋 Filing Types Available on ForgeUp Filings Sourced from BSE corporate announcements (equity segment). Companies covered are BSE-listed and most are also listed on NSE. We show only material filings.
Financial Results Orders Dividend Buyback Merger / Acquisition Board Meeting Outcome Fundraise (QIP / Rights / FPO) Regulatory / Court Order Credit Rating Change Promoter Pledge Update Management Change Joint Venture / MOU Delisting Bonus Shares Stock Split
Data sourced from BSE India corporate announcements. More categories will be added over time.
Nath Bio-Genes (India) Ltd

Nath Bio-Genes Q2 FY27 PAT fell 46% to INR 23 Million; H1 FY27 Revenue up 13%

RESULTS ▼ Concern Flagged MEDIUM RISK
📅 Filed on BSE: 16 Nov 2026, 10:05 AM IST  ·  BSE ID: cc2a0608-0661-44be-b760-6bb47846d507
View Original BSE Filing (PDF)
💡
In Simple Terms
The company's quarterly profit dropped significantly, though half-year revenue increased with higher finance costs.
🤖 AI Summary
  • Nath Bio-Genes reported Q2 FY27 Total Revenue of INR 373 Million, a 6% decrease from Q2 FY26.
  • Profit After Tax (PAT) for Q2 FY27 stood at INR 23 Million, marking a 46% decline compared to Q2 FY26.
  • For H1 FY27, Total Revenue increased by 13% to INR 3,601 Million from H1 FY26's INR 3,199 Million.
  • H1 FY27 PAT decreased 18% to INR 349 Million, down from INR 424 Million in H1 FY26.
  • Finance Costs for Q2 FY27 increased 67% to INR 55 Million, compared to INR 33 Million in Q2 FY26.
🔢 Key Numbers - exact figures from BSE filing, not rounded
Total Revenue Q2 FY27
373 INR Mn
-6%
PAT for the Period Q2 FY27
23 INR Mn
-46%
Total Revenue H1 FY27
3,601 INR Mn
13%
PAT for the Period H1 FY27
349 INR Mn
-18%
Finance Cost Q2 FY27
55 INR Mn
67%
Finance Cost H1 FY27
93 INR Mn
50%
🏢 How This Affects the Company
📈
Business Impact
H1 FY27 revenue growth indicates an expansion in sales activities, primarily driven by paddy, cotton, and bajra, which collectively contribute 76% of sales. The decline in cotton volume by 2.29% due to monsoon affected overall performance.
💰
Financial Impact
The increase in finance costs by 67% in Q2 FY27 and 50% in H1 FY27 has compressed profitability, leading to a 46% drop in Q2 PAT. Despite H1 revenue growth, PBT and PAT declined due to higher expenses.
⚙️
Operational Impact
The company maintains a diversified product portfolio across cereals, cotton, oilseeds, vegetables, and PNS. Supply chain infrastructure includes 20,000 distributors and dealers, 17 branch offices, 10 processing plants, and warehouses across 23 states.
⚠️
Risk Impact
Increased finance costs and a decline in Q2 PAT indicate pressure on the company's financial efficiency. Adverse weather conditions, such as the monsoon impacting cotton volumes, introduce external operational risks to revenue generation.
👥 What This Means For Shareholders
✅
Action Required
No specific action is required by shareholders based on this financial results presentation.
👤
Who Is Affected
All shareholders are affected by the company's financial performance, including the 46% decline in Q2 FY27 PAT and 18% decline in H1 FY27 PAT, which impacts earnings per share.
🔍
Management Signal
Management continues to focus on revenue growth, with H1 FY27 revenue increasing by 13%, but also faces challenges in managing finance costs which significantly increased.

For information only. Not investment advice. ForgeUp is not SEBI-registered.

👁 Watch List - track these upcoming events
Q3 FY27 financial results — monitor PAT trend and finance cost management.
Management commentary — review further details on H1 FY27 performance drivers.
Updates on cotton crop volumes — assess monsoon impact on sales in future periods.
MEDIUM RISK Significant PAT decline and increased finance costs signal financial pressure, requiring close monitoring of future performance.
💡 Investor Takeaway
Nath Bio-Genes reported Q2 FY27 Profit After Tax (PAT) of INR 23 Million, a 46% decrease from Q2 FY26. H1 FY27 Total Revenue grew 13% to INR 3,601 Million, but PAT decreased 18% to INR 349 Million. Finance costs rose 67% in Q2 FY27 to INR 55 Million.
⚖️ Strengths & Concerns

✅ Positives

  • H1 FY27 Total Revenue grew 13% to INR 3,601 Million, indicating business expansion compared to H1 FY26.
  • Gross Profit for H1 FY27 increased 13% to INR 1,922 Million from H1 FY26, matching revenue growth percentage.

⚠️ Concerns

  • Q2 FY27 Profit After Tax (PAT) fell 46% to INR 23 Million from INR 42 Million in Q2 FY26.
  • Finance Costs significantly increased by 67% in Q2 FY27 to INR 55 Million and 50% in H1 FY27 to INR 93 Million.
📅 Company Track Record
Nath Bio-Genes (India) Ltd's previous filing on November 14, 2026, also reported Q2 FY27 net profit fell 45.97% to Rs. 226.97 Lakhs YoY, consistent with the decline highlighted in this presentation. The Board meeting for Q1 FY27 results was scheduled for July 29, 2026.

Based on publicly available historical data. For context only.

❓ Frequently Asked Questions
What was Nath Bio-Genes' Total Revenue for Q2 FY27?
Nath Bio-Genes reported Total Revenue of INR 373 Million for Q2 FY27, a 6% decrease from INR 398 Million in Q2 FY26.
What was Nath Bio-Genes' Profit After Tax (PAT) for Q2 FY27?
The Profit After Tax (PAT) for Nath Bio-Genes in Q2 FY27 was INR 23 Million, a 46% decrease compared to INR 42 Million in Q2 FY26.
How did Nath Bio-Genes' H1 FY27 Total Revenue compare to the prior year?
Nath Bio-Genes' Total Revenue for H1 FY27 increased by 13% to INR 3,601 Million, up from INR 3,199 Million in H1 FY26.
What was the change in Nath Bio-Genes' Finance Cost in Q2 FY27?
Nath Bio-Genes' Finance Cost in Q2 FY27 increased by 67% to INR 55 Million, compared to INR 33 Million in Q2 FY26.
What crops primarily contributed to Nath Bio-Genes' H1 FY27 sales?
Paddy, cotton, and bajra were the main contributors to Nath Bio-Genes' H1 FY27 sales, accounting for 76% of total reported sales.

Questions based on this BSE filing only. For information purposes.

You've read one filing

There are 32,000 more, and one of them is about a company you own

Follow a company and we'll email you the moment it files again - explained, not just forwarded. Free.

  • Follow companies and get filings by email
  • Save any filing to read later
  • Two full AI analyses every month, free

No card needed. Sign in with Google in two taps.

⚠️ For Information Only - Not Investment Advice
ForgeUp Filings provides AI-generated summaries of public BSE exchange announcements (equity segment) for informational purposes only. Nothing here constitutes investment advice or a recommendation to buy, sell, or hold any security. ForgeUp is not a SEBI-registered investment advisor. All financial numbers are sourced directly from BSE filings and shown as-is. Past data is historical only. Please consult a qualified financial advisor before making investment decisions. Data sourced from BSE India public disclosures.
🔍
Sign in to use filters
Sign in free with Google to filter filings by category, market cap and sector - takes 5 seconds.

Live IPO, GMP and market updates on Telegram

IPO open and close dates, grey market premium moves, subscription figures, allotment and listing days, and the market updates worth knowing about, posted on the channel as they happen.

Join the channel